TEL AVIV, Israel--(BUSINESS WIRE)--Feb. 20, 2004--Tissera, Inc. (OTCBB:TSSR - News), a biotechnology company dedicated to developing novel tissue precursor regeneration technologies to address a myriad of fatal illnesses where an organ transplantation is necessary, announced today that it has completed an equity private placement with a group of individual and institutional investors resulting in net cash proceeds to the Company of $1.6 million.

"We are very encouraged by this funding which will allow Tissera to advance its research and development, to move forward with its plans for animal model and preclinical trials, and to expand the Company's infrastructure and technological capabilities," stated Dr. Vicki Rabenou, CEO.

"The growing interest by the investment community in our technology and its potential life-saving capabilities is encouraging. We offer new hope to patients and I am glad this message is getting across clearly," Dr. Rabenou concluded.

For more information, please visit: www.tissera.com.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera licensed the worldwide exclusive rights to the technology developed at the Weizmann Institute of Science in Israel led by Professor Yair Reisner. In this research, scientists successfully implanted embryonic human and porcine kidney precursor tissues in mice, which grew into functional kidneys. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."